The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats
スポンサーリンク
概要
- 論文の詳細を見る
- 2006-08-20
著者
-
Shibasaki Masayuki
Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Shibasaki Masayuki
Pharmacology Laboratories Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.
-
Nakano Ryosuke
Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
KUROSAKI Eiji
Pharmacology Laboratories Institute for Drug Discovery Research, Yamaguchi Pharmaceutical Co Ltd.
-
SHIMAYA Akiyoshi
Pharmacology Laboratories Institute for Drug Discovery Research, Yamaguchi Pharmaceutical Co Ltd.
-
Kurosaki Eiji
Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Nakano Ryosuke
Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.
関連論文
- YM-231146, a Novel Orally Bioavailable Inhibitor of Vascular Endothelial Growth Factor Receptor-2, Is Effective against Paclitaxel Resistant Tumors(Pharmacology)
- The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats
- The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats
- Hypoglycemic Agent YM440 Ameliorates the Impaired Hepatic Glycogenesis After Glucose Loading by Increasing Glycogen Synthase Activity in Obese Zucker Rats